You just read:

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis

News provided by

Enteris BioPharma, Inc.

Jul 11, 2019, 08:30 ET